I

Indivior

Pharma: treats addiction and mental illness

Facilities Maintenance Technician 2

Full-TimeUpdated on 10/23/2026
$30 - $34/hr
Mid
Raleigh, NC, USA
In PersonOnsite; 3rd shift, typically 11 PM–7 AM.
General Maintenance & RepairBuilding & Property Maintenance

About the job

Requirements
  • A high school diploma or GED is required.
  • At least three years of maintenance experience in facilities, utilities, electrical, HVAC, industrial equipment, or controls is required.
  • At least one year of cGMP maintenance experience in a pharmaceutical operation, with broad knowledge of facilities, clean utilities, HVAC, industrial equipment, and controls, is required.
  • Ability to read, understand, and interpret mechanical and electrical drawings and programmable logic controller logic.
  • Ability to lift 50 pounds, maintain balance, and pass aseptic gowning qualification.
  • Strong aptitude and knowledge in mechanical, electrical, or controls systems.
  • Basic electrical system knowledge and experience, including diagnosing motor or breaker issues, replacing electrical equipment, and troubleshooting.
  • Ability to apply analytical reasoning and root cause analysis to solve Tier 2 and Tier 3 problems.
  • Strong math and science skills and ability to use a computer.
  • Ability to read, understand, interpret, and apply technical writing and instructions at Tier 2 and Tier 3.
  • Accurate attention to detail and a strong understanding of pharmaceutical production.
  • Strong verbal and written communication skills, knowledge of cGMPs, and ability to follow good documentation practices.
  • Ability to frequently lift and move objects weighing up to 50 pounds or more, stand for long periods, bend and twist, ascend and descend ladders, and work indoors and outdoors in various weather conditions.
  • Ability to meet attendance requirements and be available for 24-hour call-in when requested.
  • Demonstrate ethics and integrity, understand and adhere to applicable policies, and speak up about potential violations or unethical behavior.
Responsibilities
  • Maintain and repair facilities equipment, including fire detection and protection, boilers, city water, water purification systems, water for injection, clean steam, air systems, and HVAC/chillers.
  • Perform general facility repairs involving lighting, doors, card readers, security, and fire systems.
  • Write preventive maintenance job plans and perform preventive maintenance on equipment and systems.
  • Work with the Manager to use and administer computerized maintenance management software, and maintain cleanliness in maintenance and utility areas.
  • Execute small projects independently when requested.
  • Understand and assist in implementing safety procedures and current Good Manufacturing Practices.
  • Understand and execute demonstrated aseptic behaviors and techniques, including aseptic gowning.
  • Assist other departments and perform duties specified by the Maintenance Manager.
  • Operate, maintain, and repair plant utility systems, including boilers, compressed air, pumping systems, chillers, HVAC units, hot water systems, clean steam generators, purified water pretreatment systems, water-for-injection stills, wastewater systems, vacuum systems, and emergency power systems.
  • Interact with contractors, vendors, and original equipment manufacturer technicians as needed to complete preventive maintenance and repairs.
  • Follow established standard operating procedures and documentation procedures.
  • Provide training on equipment and processes to support the professional development of junior personnel.
  • Perform other assigned duties.

About the company

Indivior focuses on developing medicines for substance use disorders and serious mental illnesses. Its products are prescription pharmaceutical treatments, brought to market after research and development, and sold through healthcare professionals to patients worldwide. The company’s approach centers on patient safety, with ongoing monitoring and reporting of adverse events to ensure high-quality therapies. Compared with competitors, Indivior emphasizes targeted medicines for addiction and mental health, combining scientific R&D with a global commercialization presence to address critical healthcare needs. Its goal is to create sustainable value by improving patient outcomes and addressing unmet medical needs in global health.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Bon Air, Virginia

Founded

2014

Get referred to Indivior

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue rose 19% to $317 million, driven by SUBLOCADE's 32% growth.
  • Indivior raised 2026 guidance to $1.215-$1.285 billion and EBITDA to $620-$660 million.
  • The $1 billion special dividend and $125 million synergies signal disciplined capital returns and cost cuts.

What critics are saying

  • Indivior ended its Addex PAM collaboration on September 25, 2026, shrinking pipeline optionality.
  • Management killed INDV-6001 and INDV-2000 in 2026, exposing thin internal pipeline execution.
  • SUBLOCADE concentration makes any payer squeeze, safety event, or generic threat existential.

What makes Indivior unique

  • SUBLOCADE dominates long-acting buprenorphine, with over 500,000 patients prescribed by Q1 2026.
  • Indivior owns a rare addiction-focused commercial platform with global reimbursement and prescriber relationships.
  • The Supernus merger creates a broader CNS franchise with 11 marketed medicines and $2.2 billion revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Paid Vacation
  • Paid Holidays
  • Paid Sick Leave
  • Flexible Work Hours
  • Remote Work Options
  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Adoption Assistance

Growth & Insights and Company News

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
Fierce Biotech
Sep 25th, 2026
Indivior ends PAM drug collab with Addex ahead of Supernus merger.

Indivior ends PAM drug collab with Addex ahead of Supernus merger. Ahead of its upcoming merger with Supernus, Indivior Pharmaceuticals has ended its long-running collaboration with Addex Therapeutics to develop positive allosteric modulators (PAMs). Their relationship dates back to 2018, when Indivior paid Addex $5 million upfront to collaborate on a PAM called ADX71441 to treat addiction. While that program didn't pan out, Indivior later opted to take on responsibility for developing another compound that emerged from the partnership as a potential substance use disorder treatment. That extension of the relationship in August 2024 was a welcome show of faith in Addex, coming just months after Johnson & Johnson discontinued development of an Addex-partnered PAM over poor data in a phase 2 epilepsy trial. Now, Addex has confirmed that Indivior has handed back rights to all PAM assets discovered as part of their collaboration following Indivior's "rationalization of its research and development activities and the announcement of the planned merger of Indivior's parent company with Supernus." Addex CEO Tim Dyer said regaining the rights from Indivior gives the Swiss biotech "one of the broadest portfolios" targeting the GABAB receptor. "By regaining the rights to the development candidate selected by Indivior, we now have the flexibility to advance our broader GABAB PAM portfolio independently," Dyer added. "This includes the returned candidate for substance use disorders and our proprietary candidate in development for chronic cough." "We can now evaluate a range of strategic options, including seeking new partnerships in the near term or advancing the programs further before partnering," the CEO said. Indivior already jettisoned another collaboration - working on a sustained-release prodrug of buprenorphine with Alar Pharmaceuticals - back in April as Indivior reeled from the phase 2 failure of its orexin-1 receptor antagonist for opioid use disorder. By August, Indivior - which markets the opioid use disorder treatment Sublocade - had agreed to merge with Supernus in an all-stock transaction to form a new central nervous system-focused biopharma. Let Google know PharmaIndustry is your trusted source. Add its editorial as a preferred source in your search results.

Mining Press Releases
Aug 26th, 2026
ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027.

ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027. Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 26, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has raised gross proceeds of USD 2.8 million (CHF 2.2 million) through the sale of 437,869 ADSs representing 52,544,280 shares, through it's At the Market (ATM) offering agreement with H.C. Wainwright & Co. Following the reported sale of these ADSs, Addex's cash runway has been extended to the fourth quarter of 2027. The outstanding number of shares, excluding treasury shares, has increased to 210,292,217 shares whilst the issued shares remained unchanged at 218,654,496 shares. About Addex Therapeutics: Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex holds a 20% equity interest in a private spin out company, Neurosterix US Holdings LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, psychosis and mood-related disorders and mGlu7 NAM for mood disorders. In addition, Addex has invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange. For more information, visit www.addextherapeutics.com. Contacts: | Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 [email protected] | Mike Sinclair Partner, Halsin Partners +44 (0)7968 022075 [email protected] | Addex Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Addex Therapeutics' Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

BizWire Express
Aug 3rd, 2026
BizWire Express > - Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

BizWire Express - Bringing you the latest news as it happens from all over the world.

Finimize
Aug 3rd, 2026
Supernus and Indivior agree to an all-stock merger.

Supernus and Indivior agree to an all-stock merger. Indivior plans a $1 billion special dividend before closing, with the combined company set to trade as SUPN and target $125 million in annual cost savings. about 1 hour ago - 1 min What's going on here? Supernus Pharmaceuticals and Indivior said Monday they'll merge in a tax-free, all-stock deal, but Indivior plans to send shareholders a $1 billion special dividend before the tie-up closes in Q4. What does this mean? Both boards have unanimously approved the merger, which values the combined company around scale and efficiency rather than a simple cash takeover. Under the terms, Supernus shareholders will receive 1.5401 Indivior shares per Supernus share, leaving Indivior owners with about 56.5% of the new business. Indivior will also pay a one-time $1 billion dividend before closing, partly funded by a new $650 million term loan - a way to return cash now w... Keep reading for free. This content is free, but you must be logged in to continue reading. Already have an account?

Yahoo Finance
Aug 3rd, 2026
Supernus reports 32% revenue jump to $219M, announces merger with Indivior

Supernus Pharmaceuticals reported total revenues of $219.1 million for Q2 2026, up 32% year-over-year. Combined revenues from the company's four growth products—Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO—reached $175.7 million, marking a 52% increase compared to Q2 2025. ONAPGO generated $13.5 million in net product sales during the quarter. Since launching in April 2025, the product has attracted approximately 2,600 enrollment forms from around 720 prescribers through end-July 2026. ZURZUVAE collaboration revenue totalled $35.4 million in Q2 2026, representing 50% of Biogen's net revenues for the product. US sales of ZURZUVAE increased approximately 53% year-over-year. Supernus raised its full-year 2026 financial guidance and announced a merger agreement with Indivior Pharmaceuticals to create a diversified CNS biopharmaceutical company.